Early trial tests new drug combo for tough cancers
NCT ID NCT01281176
Summary
This early-stage study is testing different dose schedules of the drug vorinostat when given with standard chemotherapy drugs (carboplatin or paclitaxel) in patients with advanced solid tumors. The main goal is to understand how the body processes the drugs, check for safety, and look for biological signs of how vorinostat works. It involves a small group of patients to gather initial information for future research.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.